medigraphic.com
ISSN 2448-8909 (Print)

2003, Number 6

<< Back

Med Crit 2003; 17 (6)

Comparative study of TNK-tPA vs streptokinase for the treatment of acute myocardial infarction in a general intensive care unit

Mendoza RM, Acevedo TJL, López GA, Nicolás FA

Language: Spanish
References: 22
Page: 210-215
PDF size: 84.68 Kb.


ABSTRACT

Objective: To demonstrate that TNK-tPA bolus applied to patients with acute myocardial infarction improve survival rate to 30 days in comparison with the use of streptokinase (SK) infusion.
Design: Prospective study.
Setting: ICU of a communitary hospital of Mexico, City.
Patients: Twenty-six patients were studied during a 6-month period: 13 of them received TNK-tPA in bolus and 13 streptokinase infusion (in 30 minutes).
Results: Thirty patients (nine men, four women, 12 ‹75 yrs old), received TNK-tPA; they had history of diabetes mellitus and obesity. Myocardial infarction site was anterior 53.8%, posteroinferior 42.6% and anteroseptal 38.5%. Arrhythmias were the main adverse effect related with the drug. The other13 patients (nine men, four women, 11 ‹75 yrs old) were treated with SK; they had history of diabetes mellitus and obesity also. Myocardial infarction site was anterior (53.8%, upper-lateral 42.6% and large anterior 23.1%. Main complications were arrhythmias. One patient died.
Conclusion: Both TNK-tPA and SK were effective in the treatment of patients with acute myocardial infarction. No patient died due to the use of these drugs.


REFERENCES

  1. Meaney E, Rivera JM, Shuchieib R, Gómez-Álvarez E. Programa de actualización continua para cardiólogos (PAC-Cardio-I). No B4 México, DF; 1998.

  2. Braundwald E. Tratado de Cardiología Médica. Medicina cardiovascular. 4ª Ed. 1993;II:1299-1510.

  3. Sackett DL, Rosemberg WC, Gray JAM et al. Evidence based medicine. What it is and what it isn’t? Br J Med J 1996;3112:17-72.

  4. Archivo del Hospital General la Villa. 1999.

  5. Lacy MC. Cardiopatía isquémica en México: Fisiopatología, comportamiento clínico. México, 1996:83-84.

  6. Braunwald E. The open artery theory is alive and web again. N Engl J Med 1993;329:1650-2.

  7. The GUSTO investigator and international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.

  8. Jones PH, Gotto AM. Prevention of coronary in 1994. Heart Dis Stroke 1994;3:290.

  9. Neuhaus KL, Von essen R, Tebbe U et al. Improved thrombolysis in acute myocardial infarction with front loaded administration of alteplase; results of the rt-PAAPSAC patency study (TAPS). J Am Coll Cardiol 1994;19: 885-91.

  10. The GUSTO angiographic investigator. The comparative effect of tissue plasminogen activator streptokinase, or both on coronary artery patency ventricular function and survival after acute myocardial infarction. N Engl J 1993;229:1615-22.

  11. Cannon C, Mcabe CH, Diver DJ et al. Comparison of front loaded recombinat tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: result of the thrombolysis in myocardial infarction (TIMI 4). J Am Coll Cardiol 1994;24:11602-110.

  12. Cannon CP, Braundwal E. Time the reperfution: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996;3:109-117.

  13. Cannon CP, Braundwal E. GUSTO, TIMI and case for rapid reperfusion. Act Cardiol 1994;49:1-8.

  14. Grupo Italiano para el estudio de la estreptoquinasa en el infarto al miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. The Lancet 1986;1:397-401.

  15. Weaver WD, Cerqueira M, Hallstrom A et al. prehospital-initiated vs hospital initiated thrombolytic therapy. Myocarial infarction triage and intervention trial. JAMA 1993;270: 1211-6.

  16. The European Myocardial Infarction Project Group, prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329: 383-9.

  17. Rawles J. On behalf of the great group having of mortality at 1 year by domiciliary thrombolysis in the grammpran region early anisteplase trial (Great). J Am Coll 1994;23:1-5.

  18. Keyt BA, Paoni NF, Refino CJ et al. Faster-acting and more potent from of tissue plasminogen activator procnati. Acad Sci USA 1994;91:3670-4.

  19. National Heart Lung and Blood Institute Morbidity and mortality: 1992.

  20. Benedict CR, Refino CJ, Keyt BA et al. New variant of human tissue plasminogen activator (tPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human tPA. Circulation 1995;92:3032- 3040.

  21. American Heart Association 1992. Dallas Texas.

  22. Colient T. Improved thrombolytic therapy. The Lancet 1994;342:34.




2020     |     www.medigraphic.com